2024年1月25日,浙江大学医学院附属第一医院骨髓移植中心施继敏教授团队在《Cell Transplantation》杂志在线发表论文"Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients With Acute Myeloid Leukemia Harboring KMT2A ...
The additional cytogenetic and molecular diagnostics, revealing a KMT2A rearrangement, was decisive for the confirmation of AML. Conclusion. This case highlights the challenges of diagnosing KMT2A‐rearranged monocytic AML and the importance of careful morphological assessment in partners...
The KMT2A rearrangement stratifies them to receive higher risk therapy with MRD response guiding furt treatment decisions, including the recommendation for HSCT in first complete remission in some protocols. The Ponte di Legno group have conducted two large international retrospective studies to assess ...
3. A study of DSP-5336 in relapsed/refractory AML/ ALL with or without MLL rearrangement or NPM1 mutation. ClinicalTrials.gov. Updated January 18, 2024. Accessed July 15, 2024.
2. A study of SNDX-5613 in R/R leukemias including those with an MLLr/KMT2A gene rearrangement or NPM1 mutation (AUGMENT-101). ClinicalTrials.gov. Updated March 25, 2023. Accessed March 26, 2024. 3. Syndax presents positive data from pivotal AUGMENT-101 trial of revumenib in relapsed/...
Notably, a complex rearrangement with YAP1 consistent with YAP1–KMT2A–YAP1 fusion was detected in most cases, with preservation of KMT2A CxxC-binding domain in the YAP1–KMT2A–YAP1 fusion and concurrent deletions of corresponding exons in KMT2A. The tumors often affected younger adults (...
KMT2A rearrangement results in assembly of a large multi-protein complex that results in aberrant transcription and epigenetic dysregulation (e.g. high level of H3K79 methylation) through recruiting excessive DOT1L, H3K79 methyltransferase, which interacts with multiple KMT2A rearrangement partners [39...
4Thomas X. Small molecule menin inhibitors: novel therapeutic agents targeting acute myeloid leukemia with KMT2A rearrangement or NPM1 mutation. Oncol Ther. 2024 Mar;12(1):57-72.https://doi.org/10.1007/s40487-024-00262-x 5Cierpoclo T, Grembecka J. Challenges and ...
Previously in December 2022, the FDA granted a breakthrough therapy designation to revumenib for adult and pediatric patients with R/R acute leukemia who harbor a KMT2A rearrangement.2 Phase 1 data from the AUGMENT-101 trial, an open-label, dose-escalation and dose-expansion study ev...
Revumenib (SNDX-5613) is a potent and selective oral inhibitor of menin-KMT2A interaction with Ki of 0.149 nM and IC50 between 10 and 20 nM, which can be used in the study of acute leukemia with MLL gene rearrangement. 靶点活性 Menin-MLL:10-20 nM 体外活性 方法:将原代患者来源的 NUP...